Loading
·
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
The quarterly reports for this company are not available yet. Please check back later.
In the mean time, check out some related stocks.